These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 4056853)

  • 1. Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma.
    Maral J; Poisson M; Pertuiset BF; Mashaly P; Weil M; Jacquillat C; Grillo-Lopez AJ
    J Neurooncol; 1985; 3(3):245-9. PubMed ID: 4056853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
    Halperin EC; Gaspar L; Imperato J; Salter M; Herndon J; Dowling S
    Am J Clin Oncol; 1993 Aug; 16(4):277-83. PubMed ID: 8392285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.
    Curt GA; Kelley JA; Kufta CV; Smith BH; Kornblith PL; Young RC; Collins JM
    Cancer Res; 1983 Dec; 43(12 Pt 1):6102-5. PubMed ID: 6640549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
    Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
    Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
    Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
    J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations.
    Schold SC; Friedman HS; Bjornsson TD; Bigner DD
    Cancer Res; 1984 Jun; 44(6):2352-7. PubMed ID: 6722774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of diaziquone in patients with head and neck cancer.
    Muñiz F; Vélez-García E; Neidhart JA; Bender JF; Becker M; Grillo-Lopez AJ
    Cancer Chemother Pharmacol; 1987; 19(3):265-8. PubMed ID: 3581421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
    Schold SC; Herndon JE; Burger PC; Halperin EC; Vick NA; Cairncross JG; Macdonald DR; Dropcho EJ; Morawetz R; Bigner DD
    J Clin Oncol; 1993 Jan; 11(1):77-83. PubMed ID: 8418246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
    Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
    J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study.
    Taylor SA; McCracken JD; Eyre HJ; O'Bryan RM; Neilan BA
    J Neurooncol; 1985; 3(2):131-5. PubMed ID: 2993536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council.
    Haid M; Khandekar JD; Christ M; Johnson CM; Miller SJ; Locker GY; Merrill JM; Reisel H; Hatfield A; Lanzotti V
    Cancer; 1985 Sep; 56(6):1311-5. PubMed ID: 4027870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diaziquone (AZQ).
    Bender JF; Grillo-Lopez AJ; Posada JG
    Invest New Drugs; 1983; 1(1):71-84. PubMed ID: 6381377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
    Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
    J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of diaziquone (AZQ) in advanced malignant melanoma.
    Høst H; Joss R; Pinedo H; Bruntsch U; Cavalli F; Renard G; van Glabbeke M; Rozencweig M
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):295-8. PubMed ID: 6681775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with recurrent primary brain tumors with AZQ.
    Schold SC; Friedman HS; Bjornsson TD; Falletta JM
    Neurology; 1984 May; 34(5):615-9. PubMed ID: 6538653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of diaziquone in children with recurrent or progressive primary brain tumors: a report from the Childrens Cancer Study Group.
    Ettinger LJ; Ru N; Krailo M; Ruccione KS; Krivit W; Hammond GD
    J Neurooncol; 1990 Aug; 9(1):69-76. PubMed ID: 2213117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Kligerman AD; Erexson GL; Wilmer JL; Schold SC
    Cancer Res; 1987 Jan; 47(2):631-5. PubMed ID: 3791247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report.
    Tapazoglou E; Kish J; Ensley J; Al-Sarraf M
    Am J Clin Oncol; 1988 Aug; 11(4):474-8. PubMed ID: 3407628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trial of diaziquone in the treatment of patients with recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; Stehman FB; Malfetano J
    Cancer Treat Rep; 1986 Sep; 70(9):1127-8. PubMed ID: 3742494
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, diazaquone, NSC 182968).
    Sigman LM; Van Echo DA; Whitacre MY; Aisner J; Budman DA; Shulman P
    Am J Clin Oncol; 1986 Feb; 9(1):79-82. PubMed ID: 3953494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.